NASDAQ:LBRX LB Pharmaceuticals (LBRX) Stock Price, News & Analysis $37.33 -0.47 (-1.24%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$37.37 +0.04 (+0.11%) As of 09/25/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About LB Pharmaceuticals Stock (NASDAQ:LBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LB Pharmaceuticals alerts:Sign Up Key Stats Today's Range$36.99▼$38.5750-Day Range$30.90▼$49.4852-Week Range$13.36▼$50.16Volume398,935 shsAverage Volume289,588 shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$49.63Consensus RatingModerate Buy Company Overview LB Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious neuropsychiatric disorders. The company’s lead product candidate, LB-102, is a long-acting injectable antipsychotic being developed for the treatment of schizophrenia. LB-102 is designed to provide sustained delivery of its active pharmaceutical ingredient and potentially support adherence compared with daily oral therapies. LB Pharmaceuticals is evaluating the candidate through clinical development intended to assess its safety, tolerability, pharmacokinetics and effectiveness in people with schizophrenia. The company’s activities are centered on advancing its pipeline through clinical trials and regulatory development. Publicly available information about LB Pharmaceuticals’ broader product portfolio, geographic operations and leadership is limited.AI Generated. May Contain Errors. Read More LB Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreLBRX MarketRank™: LB Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 499th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingLB Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialLB Pharmaceuticals has a consensus price target of $49.63, representing about 32.9% upside from its current price of $37.33.Amount of Analyst CoverageLB Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about LB Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for LB Pharmaceuticals are expected to grow in the coming year, from ($5.78) to ($5.08) per share.Price to Book Value per Share RatioLB Pharmaceuticals has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.48% of the float of LB Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLB Pharmaceuticals has a short interest ratio ("days to cover") of 21.45, which indicates bearish sentiment.Change versus previous monthShort interest in LB Pharmaceuticals has recently increased by 6.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLB Pharmaceuticals does not currently pay a dividend.Dividend GrowthLB Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.40 News SentimentLB Pharmaceuticals has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for LB Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added LB Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LB Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.80% of the stock of LB Pharmaceuticals is held by insiders.Percentage Held by InstitutionsLB Pharmaceuticals has minimal institutional ownership at this time.Read more about LB Pharmaceuticals' insider trading history. Receive LBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LB Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LBRX Stock News HeadlinesLB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion OpportunitySeptember 18, 2026 | seekingalpha.comLB Pharmaceuticals Appoints Susan Kozauer As CMOSeptember 15, 2026 | rttnews.comIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.September 26 at 1:00 AM | Banyan Hill Publishing (Ad)LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical OfficerSeptember 15, 2026 | markets.businessinsider.comLB Pharmaceuticals Appoints Susan G. Kozauer, M.D.September 15, 2026 | globenewswire.comIPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?September 9, 2026 | investors.com2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO AppointmentSeptember 4, 2026 | finance.yahoo.comLB Pharmaceuticals to Participate in Upcoming September Investor EventsSeptember 3, 2026 | globenewswire.comSee More Headlines LBRX Stock Analysis - Frequently Asked Questions How have LBRX shares performed this year? LB Pharmaceuticals' stock was trading at $22.26 on January 1st, 2026. Since then, LBRX shares have increased by 67.7% and is now trading at $37.33. How were LB Pharmaceuticals' earnings last quarter? LB Pharmaceuticals Inc (NASDAQ:LBRX) announced its quarterly earnings data on Tuesday, August, 11th. The company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.87. When did LB Pharmaceuticals IPO? LB Pharmaceuticals (LBRX) raised $285 million in an IPO on Thursday, September 11th 2025. The company issued 19,000,000 shares at a price of $14.00-$16.00 per share. Who are LB Pharmaceuticals' major shareholders? LB Pharmaceuticals' top institutional shareholders include Wellington Management Group LLP (0.18%), Bank of New York Mellon Corp (0.19%), Great Lakes Advisors LLC (0.11%) and California State Teachers Retirement System (0.05%). View institutional ownership trends. How do I buy shares of LB Pharmaceuticals? Shares of LBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 12 days, LBRX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LBRX CIK1691082 Weblbpharma.us Phone(917) 450-6581FaxN/AEmployees27Year Founded2015Price Target and Rating Average Price Target for LB Pharmaceuticals$49.63 High Price Target$78.00 Low Price Target$34.00 Potential Upside/Downside+32.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($3.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-25.92% Return on Assets-24.68% Debt Debt-to-Equity RatioN/A Current Ratio15.08 Quick Ratio15.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.91 per share Price / Book3.13Miscellaneous Outstanding Shares32,260,000Free Float30,388,000Market Cap$1.20 billion OptionableN/A BetaN/A 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:LBRX) was last updated on 9/26/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThe No. 1 move you need to make before Musk’s “Starphone” goes mainstreamTech forecaster Josh Baylin, who briefed Congress on the iPhone years before its release, says Elon Musk is bu...Stansberry Research | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LB Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share LB Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
